ArticleThe Lancet. Infectious diseases2020
Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
Article in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 64 citations in OpenAlex.
- Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches.Drug design, development and therapy · 2024Review
- COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.Genes & diseases · 2023Review
- Article
- Repurposing Vandetanib plus Everolimus for the Treatment ofCancer discovery · 2022Article
- Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality.International reviews of immunology · 2022Article
- Recent advances and developments in COVID-19 in the context of allergic diseases.Clinical and translational allergy · 2021Article
- Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications.Environmental science and pollution research international · 2021Review
- Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Review
- Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges.World journal of gastroenterology · 2021Review
- Experimental therapies under investigation for COVID-19.Journal of community hospital internal medicine perspectives · 2021Review
- Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics.Current opinion in pediatrics · 2021Review
- JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.Science advances · 2021Observational
- Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.Current medicinal chemistry · 2021Review
- The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.Microbial pathogenesis · 2021Review
- Experimental Pharmacotherapy for COVID-19: The Latest Advances.Journal of experimental pharmacology · 2021Review
- How Children Are Protected From COVID-19? A Historical, Clinical, and Pathophysiological Approach to Address COVID-19 Susceptibility.Frontiers in immunology · 2021Article
- Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges.Frontiers in microbiology · 2021Review
- Inflammatory Mechanism and Clinical Implication of Asthma in COVID-19.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2021Review
- Abnormal Airway Mucus Secretion Induced by Virus Infection.Frontiers in immunology · 2021Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.